U.S. FDA Plans Permanent Offices In China In Wake Of Heparin Scare

In the wake of a safety scare over Chinese-imported heparin API, U.S. FDA announced March 14 that it will establish permanent offices in Beijing, Guangzhou and Shanghai, staffed by eight full-time employees and five local Chinese nationals